Skip to main content
Aequus Pharmaceuticals Inc. logo

Aequus Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · AQS LEI · 54930074SO9K8QF1LJ39 TSXV Manufacturing
Open in API
Filings indexed 123 across all filing types
Latest filing 2026-03-31 M&A Activity
Country CA Canada
Listing TSXV AQS

About Aequus Pharmaceuticals Inc.

https://www.aequuspharma.ca/

Aequus Pharmaceuticals Inc. is a specialty pharmaceutical company dedicated to developing and commercializing high-quality, differentiated, and value-added products. The company focuses its sales and marketing efforts on highly specialized therapeutic areas, primarily including ophthalmology, neurology, and transplant. Aequus's strategy involves aligning with clinicians, patients, and researchers to address unmet needs within these specialty markets.

Recent filings

Filing Released Lang Actions
News release - English.pdf
M&A Activity Classification · 1% confidence The document is a corporate press release announcing the completion of the previously announced sale of the company’s ZIMED® PF product line to another party. This is a disposition of assets, effectively a divestiture transaction, which falls under merger and acquisition activity. It is neither an earnings release nor a board management update, nor a report announcement. Therefore, it best fits the M&A Activity category.
2026-03-31 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Form 52-109FV2', which is a Venture Issuer Basic Certificate used for the certification of interim filings. This is a regulatory requirement for Canadian issuers to certify the accuracy of their interim financial reports and MD&A. Since it is a regulatory filing that does not fit into the specific categories of financial reports, earnings releases, or management reports, it falls under the 'Regulatory Filings' (RNS) category.
2025-11-29 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a 'Form 52-109FV2', which is a standard Canadian regulatory filing for 'Certification of Interim Filings' by a Venture Issuer. It is a legal certification document signed by the CEO regarding the accuracy of interim financial reports. Since it is a regulatory certification document that does not fit into the specific categories of financial reports, management presentations, or announcements, it falls under the 'Regulatory Filings' category.
2025-11-29 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2 “Certification of Interim Filings” by a director under Canadian NI 52-109, certifying that the interim financial report and MD&A for the period ended June 30, 2025 contain no misrepresentations and fairly present the financial condition. It is a regulatory compliance certificate accompanying interim filings, not the interim report itself or an announcement of results, and does not fit any other specific category. Therefore it falls under the general Regulatory Filings (RNS) category.
2025-08-28 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2 “Certification of Interim Filings” under Canadian NI 52-109, consisting solely of the CEO’s certificate attesting to the review and fair presentation of the interim financial report and interim MD&A. It does not contain any actual financial statements or MD&A content (so it is not the interim report itself), nor is it an earnings release or audit report. This is a mandatory regulatory form filed along with interim filings, fitting the catch-all “Regulatory Filings” category.
2025-08-28 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is titled “Management’s Discussion and Analysis” for the six months ended June 30, 2025 and contains detailed commentary from management on the company’s financial results, operations, outlook, risks, and strategic initiatives. It follows NI 51-102 and references the interim financial statements. This is the standard MD&A report, classified under “Management Reports” (MDA).
2025-08-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.